CLYM
Price:
$1.73
Market Cap:
$117.96M
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Industry
Biotechnology
IPO Date
2021-08-10
Stock Exchange
NASDAQ
Ticker
CLYM
According to Climb Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is -23.10%. This represents a change of 293.98% compared to the average of -5.86% of the last 4 quarters.
The mean historical ROE of Climb Bio, Inc. over the last ten years is -43.11%. The current -23.10% ROE has changed -46.42% with respect to the historical average. Over the past ten years (40 quarters), CLYM's ROE was at its highest in in the March 2020 quarter at 0%. The ROE was at its lowest in in the December 2020 quarter at -68.91%.
Average
-43.11%
Median
-33.76%
Minimum
-95.83%
Maximum
-28.40%
Discovering the peaks and valleys of Climb Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 201.69%
Maximum Annual ROE = -28.40%
Minimum Annual Increase = -70.37%
Minimum Annual ROE = -95.83%
| Year | ROE | Change |
|---|---|---|
| 2024 | -34.88% | 6.86% |
| 2023 | -32.64% | -7.15% |
| 2022 | -35.15% | 23.78% |
| 2021 | -28.40% | -70.37% |
| 2020 | -95.83% | 201.69% |
The current ROE of Climb Bio, Inc. (CLYM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.22%
5-year avg
-45.38%
10-year avg
-43.11%
Climb Bio, Inc.’s ROE is greater than Entera Bio Ltd. (-16.70%), greater than Spero Therapeutics, Inc. (-125.91%), less than Seres Therapeutics, Inc. (15.31%), greater than Anixa Biosciences, Inc. (-50.24%), greater than Acumen Pharmaceuticals, Inc. (-97.41%), greater than Inovio Pharmaceuticals, Inc. (-80970.00%), greater than Actuate Therapeutics Inc (-2924.50%), greater than Turn Therapeutics Inc. (-89.74%), greater than VistaGen Therapeutics, Inc. (-90.65%), less than Agenus Inc. (59.64%),
| Company | ROE | Market cap |
|---|---|---|
| -16.70% | $96.74M | |
| -125.91% | $128.44M | |
| 15.31% | $157.07M | |
| -50.24% | $156.01M | |
| -97.41% | $119.94M | |
| -80970.00% | $108.25M | |
| -2924.50% | $170.84M | |
| -89.74% | $125.14M | |
| -90.65% | $140.27M | |
| 59.64% | $137.64M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Climb Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Climb Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Climb Bio, Inc.'s ROE?
How is the ROE calculated for Climb Bio, Inc. (CLYM)?
What is the highest ROE for Climb Bio, Inc. (CLYM)?
What is the 3-year average ROE for Climb Bio, Inc. (CLYM)?
What is the 5-year average ROE for Climb Bio, Inc. (CLYM)?
How does the current ROE for Climb Bio, Inc. (CLYM) compare to its historical average?